Sensifai Health
AI platform for pre-symptomatic inflammation detection via wearables, with 90% sensitivity proven in clinical trials for early intervention.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Seed | |
| Total Funding | 000k | ||
Related Content
Sensifai operates in the predictive health sector, utilizing an AI-powered platform to analyze data from off-the-shelf consumer wearables. The core business is the early detection of immune system activity and inflammation surges before the onset of clinical symptoms.
The company's technology is built on a proprietary AI trained on a unique bio-convergent dataset, which merges inflammatory biomarkers with wearable data. This allows the platform to convert passive signals into actionable, pre-symptomatic alerts. Clinical trials have demonstrated a 90% sensitivity in predicting these inflammatory events, enabling timely intervention by patients and healthcare providers.
Sensifai's business model targets B2B clients, including payers, healthcare providers, pharmaceutical companies, and digital health platforms. It provides these entities with life-saving insights that can scale from high-risk medical monitoring to broader population health optimization. The service aims to facilitate a shift from reactive to preventive care, potentially reducing healthcare costs and improving patient outcomes.
Keywords: predictive health, AI, wearables, inflammation detection, biomarkers, pre-symptomatic, preventive care, digital health, clinical trials, immune system